Topics

AstraZeneca Returns To Growth, But Coronavirus Likely To Hit China Revenues

00:36 EST 14 Feb 2020 | SCRIP

A long turnaround process now complete, AstraZeneca could hit double digit growth in 2020, thanks to existing products and new...

      

Related Stories

 

Original Article: AstraZeneca Returns To Growth, But Coronavirus Likely To Hit China Revenues

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca Returns To Growth, But Coronavirus Likely To Hit China Revenues"

Quick Search

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...